Latest News about GILD
Recent news which mentions GILD
   The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
   
  
  
  February 17, 2022
  From Benzinga
 
   Hookipa Pharma Stock Surges On HIV Pact With Gilead
   
  
  
  February 16, 2022
  From Benzinga
 
   The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
   
  
  
  February 16, 2022
  From Benzinga
 
   Inside Gilead's Lackluster $7.2 Billion Q4 Earnings
   
  
  
  February 16, 2022
  From Motley Fool
 
   3 Biotech Stocks to Buy in February
   
  
  
  February 16, 2022
  From Motley Fool
 
   Tracking Gilead's 4 Big Stories and a Lawsuit in 2022
   
  
  
  February 15, 2022
  From Motley Fool
 
   The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
   
  
  
  February 13, 2022
  From Benzinga
 
   Is the FDA's Partial Hold Bad News for Gilead Investors?
   
  
  
  February 12, 2022
  From Motley Fool
 
   If You Invested $100 In This Stock 20 Years Ago, Here's How Much You Would Have Today
   
  February 11, 2022
  Tickers 
   GILD
  
  
  From Benzinga
 
   Gilead's Remdesivir Retains Antiviral Activity Against Several COVID-19 Variants, Including Omicron
   
  February 11, 2022
  Tickers 
   GILD
  
  
  From Benzinga
 
   2 Green Flags For Gilead Sciences' Future
   
  
  
  February 11, 2022
  From Motley Fool
 
   Biden says it’s ‘probably premature’ for states to drop face mask requirements as Nevada and its casinos become latest to do so
   
  
  
  February 11, 2022
  From MarketWatch
 
   2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows
   
  
  
  February 10, 2022
  From Motley Fool
 
   The 7 Highest Dividend Stocks for Income Investors
   
  
  
  February 09, 2022
  From InvestorPlace
 
   Glaxo's Q4 Pharma Sales Jump 20% Boosted By COVID-19 Treatment; Prepares For Spin-Off
   
  
  
  February 09, 2022
  From Benzinga
 
   RedHill Biopharma's COVID-19 Antiviral Cuts Mortality By 70% In Remdesivir Treated Patients
   
  
  
  February 07, 2022
  From Benzinga
 
   ‘You will not believe what I’ve just found.’ Inside the ivermectin saga: a hacked password, mysterious websites and faulty data
   
  
  
  February 07, 2022
  From MarketWatch
 
   Why Jim Cramer Believes Loves Berkshire Hathaway And Rivian
   
  
  
  February 07, 2022
  From Benzinga
 
   3 Biotech Stocks That Could Make You Richer in February (and Beyond)
   
  
  
  February 05, 2022
  From Motley Fool
 
   5 Biotech Stocks to Buy to Benefit From Biden’s New Cancer Cabinet
   
  
  
  February 04, 2022
  From InvestorPlace
 
   COVID-19 treatments raked in billions of dollars in 2021. How will they do this year?
   
  
  
  February 04, 2022
  From MarketWatch
 
   How Big Are Gilead's Latest COVID Wins?
   
  
  
  February 03, 2022
  From Motley Fool
 From Benzinga
 
   The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
   
  
  
  February 02, 2022
  From Benzinga
 
   Gilead Q4 Earnings Highlights: Remdesivir Sales Fall 30%, Raises Dividend, FY22 EPS Below Estimates
   
  February 02, 2022
  Tickers 
   GILD
  
  
  From Benzinga
 
   Gilead Sciences (GILD) Q4 2021 Earnings Call Transcript
   
  February 02, 2022
  Tickers 
   GILD
  
  
  From Motley Fool
 
   12 Health Care Stocks Moving In Tuesday's After-Market Session
   
  
  
  February 01, 2022
  From Benzinga
 
   Gilead earnings slammed by legal settlement, stock falls
   
  
  
  February 01, 2022
  From MarketWatch
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.